Cognistx to Collaborate on AI Initiative to Improve the Development of Psychedelic Medicine for the Treatment of Mental Health Illnesses
Share Article
Cognistx and MagicMed Industries Inc. will develop PsyAI™, a tool designed to streamline pharmaceutical design in an effort to accelerate the modernization of psychedelic medicines.
Cognistx
“The convergence of AI and psychedelic medicine will result in a medical renaissance – all to benefit the treatment of mental health conditions,” said Cognistx CEO Sanjay Chopra. “It’s very exciting to be at the nexus of this convergence of medicine with AI technology.” PITTSBURGH (PRWEB) April 09, 2021 Cognistx (Cognistx.com), a tech firm that designs artificial intelligence (AI) business solutions, announces its partnership with MagicMed Industries Inc. (“MagicMed”), a Canadian biotech company, to develop a groundbreaking AI tool (“PsyAI™”) intended
NA Proactive news snapshot: Power REIT, Todos Medical, Ltd , WeedMD Inc, Australis Capital Inc, The Valens Company Inc, American Manganese Inc UPDATE …
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Todos Medical, Ltd , WeedMD Inc, Australis Capital Inc, The Valens Company Inc, American Manganese Inc …
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
MagicMed Industries announced another collaboration as the company begins to develop PsyAI
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
USA - English
Share this article
MagicMed Industries Inc. (CSE: MGIC reserved) (
MagicMed or the
Company ) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence (
AI ). Together the parties are building PsyAI
TM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine.
The standard pharmaceutical candidate screening process is a consistent bottleneck in bringing standard pharmaceutical candidates to market and acts as a primary determinant of eventual clinical success or failure. This paradigm is particularly challenging in the psychedelics pharmaceutical sector, owing to a limited understanding of the mechanisms underlying observed clinical dat